Thymosin Alpha-1 Dosage Protocol: Clinical Dosing, Cycling, and Stacking (2026)

Thymosin Alpha-1 Dosage: The Clinical Standard and How Biohackers Use It

Thymosin alpha-1 dosage for immune support is 1.6 mg administered subcutaneously twice weekly, spaced 3 to 4 days apart. This figure comes directly from pivotal Phase-3 hepatitis B and C trials and has been validated across sepsis, cancer adjuvant, and immune restoration protocols in over 11,000 human subjects across 30+ clinical trials.

Thymosin alpha-1 (TA-1, thymalfasin, Zadaxin) is a 28-amino acid peptide derived from thymosin fraction 5, a thymic extract first isolated in the 1970s. Unlike most peptides discussed in biohacking circles, TA-1 has a genuinely deep clinical evidence base spanning four decades, multiple Phase-3 trials, and regulatory approval in over 35 countries for chronic viral hepatitis and cancer immune support (Goldstein 2010).

What makes TA-1 different from growth hormone secretagogues or tissue-repair peptides is its target: not muscle, not collagen, not the GH axis. TA-1 acts on the immune system at a foundational level, driving T-cell maturation, dendritic cell activation, and cytokine balance. The research stack behind it is unusually solid for a compound that most Western practitioners have never prescribed.

Affiliate disclosure: This post contains affiliate links to research-grade thymosin alpha-1 through our partner. If you purchase through these links, Underground Biohacking earns a commission at no additional cost to you. We only link compounds we cover editorially.

If you want to source research-grade thymosin alpha-1 from a vetted supplier, Real Peptides carries 10 mg vials of thymalfasin with third-party CoA testing.

What Thymosin Alpha-1 Actually Does in the Body

Thymosin alpha-1 works by activating dendritic cells through p38 MAPK and NFκB signalling pathways, which drives T-cell maturation, increases natural killer cell activity, and promotes balanced Th1/Th2 cytokine production. It is an immune modulator, not an immune suppressor or a simple stimulant.

The mechanism has been characterised in detail at the cellular level. TA-1 binds Toll-like receptors TLR-2 and TLR-9 on dendritic cells, triggering their maturation and antigen-presenting capacity independent of external cytokine signals (PMC 2025). Once dendritic cells are activated, they drive naive T cells toward active CD4+ and CD8+ effector phenotypes. NK cell counts in immunocompromised states also recover under TA-1 administration.

Critically, this pathway is distinct from the hypothalamic-pituitary-gonadal axis. TA-1 does not affect testosterone, cortisol, GH, or any sex hormone. It does not interact with pituitary signalling. The endocrine system remains untouched (PMC 2006). This is relevant when stacking: there is no hormonal interference to worry about.

The cytokine output is characteristically Th1-dominant in viral and tumour contexts and shifts toward immune homeostasis in autoimmune contexts. TA-1 acts as what researchers have described as a "regulator of regulators," modulating signals rather than overwhelming them (Romani 2010).

Pharmacokinetics: What Happens After Injection

Thymosin alpha-1 is rapidly absorbed subcutaneously, reaching peak serum concentrations within two hours. The serum half-life is approximately two hours, and blood levels return to baseline within 24 hours. Despite this short half-life, clinical effects on immune markers persist for days after each dose.

This pharmacokinetic profile explains the twice-weekly dosing schedule seen across most clinical trials. You are not trying to maintain a constant serum level of TA-1. Instead, you are triggering immune signalling events that have downstream effects lasting far beyond the peptide's residence in circulation. Think of it less like a hormone that needs constant replacement and more like a signal that primes a longer biological response.

Peak serum Cmax is achieved at approximately 2 hours post-injection. After that, clearance is rapid. Yet immune markers, including HLA-DR expression and T-cell subset counts, continue to shift over the 3 to 4 days between doses (PubMed 2001). This is consistent with the downstream signalling cascade: TA-1 initiates a process that runs longer than its own presence in the bloodstream.

Standard Dosage Protocol: The Clinical Reference Point

The standard thymosin alpha-1 dosage across pivotal clinical trials is 1.6 mg subcutaneously twice weekly. This dose, roughly 900 micrograms per square metre of body surface area, was established in hepatitis B and C trials and has since been applied across sepsis, cancer adjuvant, and immune restoration contexts with consistent tolerability.

Standard Immune Support Protocol

• Dose: 1.6 mg per injection
• Frequency: Twice weekly, 3 to 4 days between injections (e.g., Monday and Thursday)
• Duration: 6 to 12 months continuous; no mandatory cycling required
• Route: Subcutaneous injection, typically abdomen or lateral thigh
• Vial reconstitution: 10 mg vial + 2 mL bacteriostatic water = 5 mg/mL; draw 0.32 mL per dose

This 1.6 mg figure comes from the trial design that produced the most robust clinical data. In the combination interferon trial (Mutchnick 1998), 109 patients received 1.6 mg SC twice weekly alongside interferon-alpha 2b. ALT normalisation occurred in 37.1% of the combination group versus 16.2% in the interferon-alone arm. The dose was well tolerated with only local injection site discomfort reported.

Loading-Dose Protocol for Acute Immune Deficit

In advanced cancer patients with very low baseline CD3+ T-cell counts, a 7-day loading protocol has been used: 3.2 mg daily for 7 days, then dropping to the standard twice-weekly maintenance dose. This is documented in clinical practice and referenced in the FDA Pharmacy Compounding Advisory Committee report (FDA 2024), which confirms TA-1 is safe at doses from 1 mg to 16 mg subcutaneously for up to 12 months.

Low-Dose Conservative Protocol

Some practitioners start at 0.8 mg twice weekly for the first two weeks before advancing to the standard 1.6 mg. There is no clinical trial data mandating this approach, but it follows standard peptide practice of establishing individual tolerability before advancing to target dose. For individuals with autoimmune conditions, a more conservative titration makes clinical sense given TA-1's potent immune-activating effects.

For subcutaneous injection technique when drawing and administering reconstituted peptides, see the subcutaneous injection technique guide.

Cycling: Do You Need to Come Off Thymosin Alpha-1?

Thymosin alpha-1 does not require mandatory cycling. Clinical trials administered TA-1 continuously for 6 to 12 months without evidence of receptor desensitisation, tolerance development, or diminishing immune response. Unlike growth hormone secretagogues, there is no endogenous feedback loop that gets blunted by continuous TA-1 use.

This is one of the features that distinguishes TA-1 from most peptides in common biohacking use. Compounds that act on the GH axis or sex hormone pathways face physiological resistance if used without breaks. TA-1 modulates an immune signalling cascade, not a feedback-regulated endocrine system. There is no equivalent of pituitary desensitisation (Goldstein 2010).

That said, many practitioners run TA-1 on an 8-week-on, 4-week-off schedule. This is not pharmacologically required but serves a practical purpose: it creates defined assessment periods where immune markers can be tracked at baseline (off) and during treatment (on). If you are monitoring with labs, structured cycling is operationally useful even if it is not biologically necessary.

The practical recommendation for most research contexts: run TA-1 for a minimum of 8 weeks at the standard dose before assessing response. Immune modulation is a slow signal; two weeks of data tells you almost nothing meaningful.

Stacking Thymosin Alpha-1 With Other Peptides

Thymosin alpha-1 stacks cleanly with most peptides because it operates exclusively on immune pathways and does not compete for receptors or create endocrine interference. Common research stacks include TA-1 with BPC-157 for immune-plus-repair protocols, TA-1 with LL-37 for antimicrobial immune support, and TA-1 with GH secretagogues for comprehensive longevity protocols.

TA-1 + BPC-157

The most commonly discussed biohacking stack pairs TA-1 with BPC-157. The logic is straightforward: BPC-157 drives tissue repair, angiogenesis, and gut healing via growth factor pathways, while TA-1 modulates the immune environment those tissues exist in. There is no pharmacological reason they cannot run simultaneously, and no receptor overlap. Both are subcutaneous peptides with different targets, different half-lives, and distinct downstream effects. See the immune peptide stacking protocols guide for full stack configurations.

TA-1 + LL-37

LL-37 is an antimicrobial peptide that operates at the innate immune interface. Stacking with TA-1 creates a two-layer immune protocol: LL-37 at the first-response level, TA-1 at the adaptive T-cell and dendritic cell level. This combination is used in research contexts focused on chronic infection burden and immune reconstitution after immune-suppressive treatments.

TA-1 With GH Secretagogues

For longevity-focused protocols that include CJC-1295/ipamorelin or MK-677, TA-1 can run alongside without modification. GH secretagogues act on the somatotropic axis; TA-1 acts on the immune axis. They operate in parallel, not in competition. The combined protocol addresses both body composition and immune competence, which is the intent of most comprehensive anti-ageing stacks.

Reconstitution and Storage

Reconstitute thymosin alpha-1 with preservative-free bacteriostatic water only. A standard 10 mg vial with 2 mL bacteriostatic water yields 5 mg per mL. Store reconstituted vials refrigerated at 2 to 8 degrees Celsius and use within 28 days. Do not freeze reconstituted peptide.

Bacteriostatic water is essential, not optional. Regular sterile water lacks the preservative (benzyl alcohol) that bacteriostatic water contains, which means contamination risk is higher and shelf life is shorter. Tap water is never appropriate. For complete guidance on reconstitution technique and storage, the reconstitution with bacteriostatic water guide covers the full procedure including syringe sizing and injection timing.

Dry lyophilised TA-1 powder is stable at room temperature for 12 to 24 months when stored away from heat and light. Once reconstituted, the 28-day refrigerated window applies. Do not leave reconstituted vials at room temperature for extended periods between doses.

Safety Profile: What 30+ Clinical Trials Show

Thymosin alpha-1 has one of the most thoroughly characterised safety profiles of any research peptide. A 2024 comprehensive review of 11,000+ subjects across 30+ clinical trials found TA-1 to be well tolerated, with mild local injection site irritation as the only consistently reported adverse effect. No significant systemic toxicity has been attributable to TA-1 in any trial.

The FDA Pharmacy Compounding Advisory Committee reviewed the TA-1 data in 2024 and documented that doses from 1 mg to 16 mg subcutaneously for up to 12 months showed no serious adverse events attributable to the compound (FDA 2024). The safety ceiling in clinical trials is 16 mg; the typical research dose is well below that threshold.

The 2024 narrative review by Dominari et al. (PubMed 2024) is the most comprehensive safety summary available. Across the 30+ trials and 11,000+ subjects, the conclusion is consistent: TA-1 is a well-tolerated immune modulator with a safety profile comparable to placebo in most comparisons.

Specific considerations for research use:

• Injection site: Rotate sites to minimise local irritation. Abdomen and lateral thigh are standard locations.
• Autoimmune conditions: TA-1 is an immune activator. Individuals with active autoimmune conditions should use caution and work with a qualified clinician before initiating any thymosin alpha-1 protocol.
• Immunosuppressive therapy: TA-1 may theoretically antagonise immunosuppressive drug regimens. This is a clinician-level consideration, not a self-managed variable.
• Pregnancy and lactation: No data exists; avoid.

Always work with a qualified clinician before making changes to your health protocol.

Clinical Evidence Summary: Sepsis, COVID-19, and Cancer

Beyond hepatitis, thymosin alpha-1 has accumulated clinical evidence across sepsis, severe COVID-19, and cancer immunotherapy contexts. A meta-analysis of sepsis trials found TA-1 reduced 28-day all-cause mortality by 23% compared to placebo (RR 0.77, 95% CI 0.59 to 0.99), making it one of the few peptides with documented mortality-reduction data in humans.

The sepsis evidence is particularly striking. The 2016 systematic review and meta-analysis (PubMed 2016) showed TA-1 administered once daily significantly reduced APACHE II severity scores (SMD -0.80, p less than 0.0001) and increased HLA-DR expression on immune cells (SMD 1.23, p=0.01), indicating genuine immune restoration in critically ill patients whose immune systems had collapsed.

In COVID-19, a 2023 systematic review (PubMed 2023) examined TA-1 in moderate-to-critical patients and found evidence of immunomodulatory benefit through T-cell and dendritic cell modulation. The data in COVID-19 is not yet at the level of the hepatitis or sepsis evidence, but the mechanistic rationale is consistent.

For cancer, preclinical data shows high-dose TA-1 combined with cyclophosphamide produced complete tumour regression 3.9 times longer than untreated controls in melanoma models (PubMed 1999). Clinical oncology use typically involves TA-1 as an adjuvant to conventional treatment, helping restore immune competence during chemotherapy-induced immunosuppression.

References

• Ershler et al. 2001. Thymosin alpha-1. PubMed.
• Mutchnick et al. 1998. Combination therapy with thymosin alpha1 and interferon for chronic hepatitis C. PubMed.
• Zignego et al. 1998. Thymosin alpha1 pilot trial for chronic hepatitis C. PubMed.
• Wu et al. 2016. Thymosin alpha-1 as immunomodulatory treatment for sepsis. PubMed.
• Liu et al. 2023. Thymosin alpha-1 in moderate to critical COVID-19. PubMed.
• Romani et al. 2006. Thymosin-alpha1 modulates dendritic cell differentiation. PMC.
• Goldstein et al. 2010. Thymosin alpha1: past clinical experience and future promise. PubMed.
• Dominari et al. 2024. Comprehensive review of the safety and efficacy of thymosin alpha-1. PubMed.
• FDA PCAC 2024. Thymosin alpha-1 bulk drug substances review.
• Romani 2010. Thymosin alpha1: the regulator of regulators. PubMed.
• Tuthill et al. 1999. High-dose thymosin alpha1 and anti-tumour efficacy. PubMed.
• PMC 2025. Immunomodulatory activity of thymosin alpha-1 on tumour cell lines.

This content is for educational purposes only. These compounds are intended for research use. Nothing here is medical advice. Always work with a qualified clinician before making changes to your health protocol.